Egetis är ett innovativt och integrerat läkemedelsbolag, fokuserat på projekt i sen klinisk utvecklingsfas för kommersialisering inom särläkemedelsområdet för behandling av allvarliga och sällsynta sjukdomar med betydande medicinska behov

PledPharma Capital Markets Day

5 februari, 2019

Stockholm, February 5, 2019. PledPharma has the pleasure of inviting investors, financial analysts and media to PledPharmas’s Capital Markets Day (CMD) on 26th March 2019.

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company has the pleasure of inviting investors, financial analysts and media to PledPharmas’s Capital Markets Day (CMD) on 26th March 2019.

Time: Tuesday March 26th, at 10:00-15:00 CET
Venue: Redeye, Mäster Samuelsgatan 42, 10th floor, Stockholm

During the CMD, the company will provide an update and in-depth view on the company strategy and its assets covering the unmet medical need, commercial opportunities, development plans and additional activities to create and enhance value.

Speakers at the CMD include the Chairman of the Board, Håkan Åström, the CEO, Nicklas Westerholm and members from the management team as well as two key opinion leaders, Dr. James Dear, Edinburgh University and Prof. Per Pfeiffer, Odense University.

Presentations are held in English and a complete agenda will be presented in advance of the event.

The CMD will be broadcasted live at www.redeye.se/live/pled-kapitalmarknadsdag-2019

To attend – sign up here!

For further information, please contact:
Yilmaz Mahshid, CFO
Tel. +46-(0)72 231 68 00

About PledPharma
PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose. The company’s most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A global phase III program is ongoing. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. A proof of principle study has been successfully completed and will serve as the basis for the continued development. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 83 00, certifiedadviser@penser.se). For more information, see http://www.pledpharma.com/



Kontakta oss

Adress: Klara Norra Kyrkogata 26, 111 22 Stockholm

Telefon: 08-679 72 10

E-post: info@egetis.com